Athira Pharma, Inc. (ATHA)
ATHA Stock Price Chart
Explore Athira Pharma, Inc. interactive price chart. Choose custom timeframes to analyze ATHA price movements and trends.
ATHA Company Profile
Discover essential business fundamentals and corporate details for Athira Pharma, Inc. (ATHA) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
18 Sept 2020
Employees
26.00
Website
https://www.athira.comCEO
Mark J. Litton
Description
Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. The company's lead product candidate is ATH-1017, a blood brain barrier-penetrating, small molecule HGF/MET positive modulator that is in LIFT-AD Phase 3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease. It also develops product candidates, which are in preclinical stage, including ATH-1019 for peripheral nervous system indications; and ATH-1020 for neuropsychiatric conditions. Athira Pharma, Inc. was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc. in April 2019. The company was incorporated in 2011 and is headquartered in Bothell, Washington.
ATHA Financial Timeline
Browse a chronological timeline of Athira Pharma, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 7 May 2026
Upcoming earnings on 25 Feb 2026
Upcoming earnings on 6 Nov 2025
EPS estimate is -$0.17.
Stock split effective on 18 Sept 2025
Shares were split 1 : 10 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 7 Aug 2025
EPS came in at -$0.18 matching the estimated -$0.18.
Earnings released on 9 May 2025
EPS came in at -$0.23 falling short of the estimated -$0.20 by -15.00%.
Earnings released on 27 Feb 2025
EPS came in at -$0.39 falling short of the estimated -$0.23 by -69.57%.
Earnings released on 7 Nov 2024
EPS came in at -$0.75 surpassing the estimated -$0.80 by +6.25%.
Earnings released on 1 Aug 2024
EPS came in at -$0.70 surpassing the estimated -$0.75 by +6.67%.
Earnings released on 15 May 2024
EPS came in at -$0.69 surpassing the estimated -$0.80 by +13.75%.
Earnings released on 22 Feb 2024
EPS came in at -$0.71 surpassing the estimated -$0.96 by +26.04%, while revenue for the quarter reached $1.66M .
Earnings released on 9 Nov 2023
EPS came in at -$0.87 matching the estimated -$0.87.
Earnings released on 10 Aug 2023
EPS came in at -$0.78 surpassing the estimated -$0.81 by +3.70%.
Earnings released on 11 May 2023
EPS came in at -$0.73 falling short of the estimated -$0.66 by -10.61%.
Earnings released on 23 Mar 2023
EPS came in at -$0.79 falling short of the estimated -$0.70 by -12.86%.
Earnings released on 10 Nov 2022
EPS came in at -$0.53 surpassing the estimated -$0.67 by +20.90%.
Earnings released on 15 Aug 2022
EPS came in at -$0.65 surpassing the estimated -$0.66 by +1.52%.
Earnings released on 12 May 2022
EPS came in at -$0.56 surpassing the estimated -$0.63 by +11.11%.
Earnings released on 24 Mar 2022
EPS came in at -$0.37 surpassing the estimated -$0.61 by +39.34%.
Earnings released on 10 Nov 2021
EPS came in at -$0.42 surpassing the estimated -$0.50 by +16.00%.
Earnings released on 16 Aug 2021
EPS came in at -$0.38 falling short of the estimated -$0.37 by -2.70%.
Earnings released on 13 May 2021
EPS came in at -$0.25 surpassing the estimated -$0.30 by +16.67%.
Earnings released on 25 Mar 2021
EPS came in at -$0.24 surpassing the estimated -$0.29 by +17.24%.
Earnings released on 12 Nov 2020
EPS came in at -$1.12 falling short of the estimated -$0.25 by -348.00%.
Earnings released on 18 Sept 2020
EPS came in at -$0.06 .
ATHA Stock Performance
Access detailed ATHA performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.